Assessing fetal hemoglobin in patients on Tranylcypromine

• Conditions: Hereditary anemia; sickle cell disease; 10018902

• Registration Number: NL-OMON41063
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Adult patients who give consent, taking Tranylcypromine for 2 months or longer, prescribed by their attending physician as part of their regular treatment.

Exclusion Criteria

Non-compliance; hemophobia.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The amount of HbF in peripheral blood. In adults the amount of HbF is normally<br /><br>less than 1% of the total amount of hemoglobin. HbF levels should be increased<br /><br>to at least 3% in order to use the results of this study for the design of a<br /><br>follow-up study investigating the effect of Tranylcypromine on HbF levels in<br /><br>sickle cell disease patients.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable.</p><br>